The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by O’Sullivan, B. J.
Right arrow Articles by Thomas, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by O’Sullivan, B. J.
Right arrow Articles by Thomas, R.
The Journal of Immunology, 2002, 168: 5491-5498.
Copyright © 2002 by The American Association of Immunologists

CD40 Ligation Conditions Dendritic Cell Antigen-Presenting Function Through Sustained Activation of NF-{kappa}B1

Brendan John O’Sullivan and Ranjeny Thomas2

Center for Immunology and Cancer Research, University of Queensland, Princess Alexandra Hospital, Brisbane, Queensland, Australia


    Abstract
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
An understanding of the biochemical control of dendritic cell (DC) differentiation/activation is essential for improving T cell immunity by various immunotherapeutic approaches, including DC immunization. Ligation of CD40 enhances DC function, including conditioning for CTL priming. NF-{kappa}B, and particularly RelB, is an essential control pathway for myeloid DC differentiation. Furthermore, RelB regulates B cell Ag-presenting function. We hypothesized that CD40 ligand (CD40L) and TNF-{alpha}, which differ in their capacity to condition DC, would also differ in their capacity to activate NF-{kappa}B. DC differentiated for 2 days from monocytes in the presence of GM-CSF and IL-4 were used as a model, as NF-{kappa}B activity was constitutively low. The capacity of DC to activate T cells following CD40L treatment was enhanced compared with TNF-{alpha} treatment, and this was NF-{kappa}B dependent. Whereas RelB/p50 translocation induced by TNF-{alpha} was attenuated after 6 h, RelB/p50 nuclear translocation induced by CD40L was sustained for at least 24 h. The mechanism of this difference related to enhanced degradation of I{kappa}B{alpha} following CD40L stimulation. However, NF-{kappa}B activation induced by TNF-{alpha} could be sustained by blocking autocrine IL-10. These data indicate that NF-{kappa}B activation is essential for T cell activation by DC, and that this function is enhanced if DC NF-{kappa}B activation is prolonged. Because IL-10 moderates DC NF-{kappa}B activation by TNF-{alpha}, sustained NF-{kappa}B activation can be achieved by blocking IL-10 in the presence of stimuli that induce TNF-{alpha}.


    Introduction
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Dendritic cells (DC)3 capture and process Ags in the periphery and present Ag in a MHC-specific context in the lymph node (1). Priming of naive CD4+ and/or CD8+ T cells is initiated by mature DC that express adhesion and costimulatory molecules, including CD40, CD58, CD80, and CD86, and that secrete cytokines supporting CTL differentiation, such as IL-12 (2, 3, 4). Inflammatory signals, microbial signals, and cognate T cell signals such as CD40 ligand (CD40L) can all induce a program of maturation in DC (5). Of importance for tumor immunotherapy, tumor microenvironments are often hostile to DC maturation due to production of cytokines such as IL-10, vascular endothelial growth factor, and TGF-{beta}. Because the presentation of Ag by immature DC may lead to tolerance, an understanding of the key elements controlling the DC maturation program is critical for designing therapies that effectively induce tumor-specific CTL and T cell help despite the potential for attenuation of DC maturation in environments such as tumors. Previously it was demonstrated that ligation of CD40 expressed by DC conditioned the DC for effective APC function, particularly CTL induction (6, 7, 8). Indeed, activation with anti-CD40 Ab could substitute for T cell help when inducing CTL in vivo. While the full range of signals that can condition DC in this way is not known, influenza viral particles could also condition DC for CTL induction (7). In keeping with the importance of CD40 ligation in the induction of CTL effectors, tumor Ag-pulsed bone marrow-derived DC treated ex vivo with soluble CD40L led to enhanced tumor protection compared with DC pretreated without soluble CD40L or treated with LPS (9).

The NF-{kappa}B family has emerged as a key transducer of inflammatory signals to the DC maturation program. The NF-{kappa}B complex comprises homodimers and heterodimers of the structurally related proteins p50, p52, RelA (p65), c-Rel, and RelB. NF-{kappa}B proteins are present in an inactive form in the cytosol, bound to inhibitor proteins called I{kappa}B. Signaling through NF-{kappa}B-inducing kinase and other kinases induces phosphorylation of I{kappa}B and nuclear translocation of NF-{kappa}B (10, 11). RelB is required for DC differentiation, as RelB-/- mice have normal numbers of peripheral immature DC such as Langerhans cells but lack mature myeloid DC (12, 13, 14). RelB, p50, and c-Rel are the major NF-{kappa}B transcription factor subunits induced during human monocyte-derived DC (MDDC) and murine Langerhans cell maturation (15, 16). We have shown that RelB/p50 nuclear translocation correlates with efficient APC function and directly enhances APC function of B cells through regulation of CD40 and MHC expression (17, 18).

Because NF-{kappa}B, and particularly RelB, is a critical control pathway for myeloid DC differentiation, we hypothesized that proinflammatory signals that differ in their capacity to condition DC for CTL induction would also differ in their capacity to activate NF-{kappa}B. DC differentiated for 2 days from monocytes in the presence of GM-CSF and IL-4 (MDDC) were used as a model in these studies because their constitutive activation of NF-{kappa}B is low, and because MDDC are used in many current and published trials of tumor immunotherapy using DC. The data indicate that CD40L signals DC through potent and sustained NF-{kappa}B stimulation.


    Materials and Methods
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Dendritic cells

Monocytes were derived from PBMC depleted of NK, B, and T cells with anti-CD56, anti-CD16, anti-CD19, and anti-CD3, as well as goat anti-mouse Ig-conjugated magnetic beads (Miltenyi Biotec, Auburn, CA) as previously described (19). MDDC were cultured for 2 days in medium supplemented with 800 U/ml GM-CSF and 400 U/ml recombinant human IL-4 (both from Schering-Plough, Sydney, Australia). To induce maturation, MDDC were incubated with 100 U/ml TNF-{alpha} (Life Technologies, Gaithersburg, MD), 500 ng/ml CD40L (Immunex, Seattle, WA), 1 µg/ml LPS (Sigma-Aldrich, St. Louis, MO), or 10 ng/ml IL-12 (R&D Systems, Minneapolis, MN). In some experiments MDDC were incubated for 30 min with BAY 11-7082 (BioMol, Plymouth Meeting, PA) and then TNF-{alpha} was added for an additional 24 h. MDDC were then washed three times before use. Neutralizing Abs anti-IL-10 (BD PharMingen, San Diego, CA) and anti-IL-12 (BD PharMingen) were used at 10 µg/ml. Control Abs were rat Ig and mouse Ig, respectively.

Flow cytometry

MDDC were stained with mAb to HLA-DR-FITC (DK22; DAKO, Carpinteria, CA), CD83 (Ancell, Bayport, MN), or CD86 (Ancell). DC labeled with unconjugated Abs against CD83 and CD86 were subsequently incubated with biotinylated rabbit anti-mouse Ig (DAKO) and then with streptavidin-FITC (DAKO). Cells were analyzed using a Coulter Epics Elite flow cytometer (Coulter Electronics, Hialeah, FL).

Cytokine ELISA

Levels of IL-10 and IL-12 p70 in supernatants from MDDC stimulated with TNF-{alpha}, CD40L, or LPS were determined using OptEIA kits (BD PharMingen) as per the manufacturer’s instructions.

Assays of APC function

MDDC were treated with mitomycin C (Sigma-Aldrich) as previously described (19). For the MLR, allogeneic T cells were purified from nylon wool nonadherent PBMC derived from healthy donors by negative selection with anti-CD19, anti-CD16, anti-CD56, anti-HLA-DR, and goat anti-mouse Ig-conjugated magnetic beads (Miltenyi Biotec) as previously described (17). Varying numbers of APC were incubated with 105 allogeneic T cells for 5 days. [3H]Thymidine (1 µCi/well; ICN Pharmaceuticals, Costa Mesa, CA) was added for the last 18 h. Plates were harvested using an automated harvester and counted using a Packard TopCount NXT (Packard Instrument, Meriden, CT). Results are expressed as mean ± SEM of triplicate wells.

Protein extraction and immunoblotting

Nuclear and cytoplasmic extracts were prepared as previously described (17), and protein estimations were conducted using a Protein Assay kit (Bio-Rad, Hercules, CA). A total of 10 µg of protein extract were separated by 8% SDS-PAGE. Following transfer to nitrocellulose (Amersham Biosciences, Sunnyvale, CA), membranes were immunoblotted with anti-RelB (sc-226), anti-p50 (sc-7178), anti-I{kappa}B{alpha} (sc-371) (all from Santa Cruz Biotechnology, Santa Cruz, CA), or anti-phospho-I{kappa}B{alpha} (Ser32; Cell Signaling Technology, Beverly, MA) Abs followed by sheep anti-rabbit HRP-conjugated Ig (SILENUS Labs, Boronia, Australia) and then detected by ECL according to the manufacturer’s instructions (Amersham Biosciences). For protein quantitation, blots were scanned using a Storm 860 (Amersham Biosciences) and analyzed by densitometry using ImageQuant 5.1 software (Amersham Biosciences).

NF-{kappa}B-binding ELISA

p50, RelB, and RelA DNA binding was detected by ELISA using a Mercury Transfactor p50 kit (Clontech Laboratories, Palo Alto, CA). A total of 10 µg of nuclear extract were bound to wells coated with NF-{kappa}B consensus oligonucleotide, then incubated with anti-RelB, anti-p50, or anti-RelA, followed by anti-rabbit HRP-conjugated Ig, and then detected by measuring color development of tetramethylbenzidine at 650 nm using a Multiskan plate reader (Labsystems, Chicago, IL).

RNA isolation and real-time quantitative PCR

RNA was extracted from 1 x 106 MDDC using TRIzol (Life Technologies) according to the manufacturer’s instructions. cDNA was synthesized using oligo(dT)20 (Promega, Madison, WI) as a primer and Expand Reverse Transcriptase (Boehringer Mannheim, Ridgefield, CT). Primers were designed using Primer Express Software (PE Applied Biosytems, Foster City, CA) and were as follows: GAPDH, 5'-GAAGGTGAAGGTCGGAGTC-3' and 5'-GAAGATGGTGATGGGATTTC-3'; RelB, 5'-GCCATTGCCTTTCACGTACCT-3' and 5'-CCCGTTTCGCCTTCTTGTC-3'; p50, 5'-GGCTACACCGAAGCAATTGAAG-3' and 5'-CAGCGAGTGGGCCTGAGA-3'; p52, 5'-CCGATTTCGATATGGCTGTGA-3' and 5'-GGTCTTTCGGCCCTTCTCA-3'; c-Rel, 5'-CCCACGCTCAGGCAATACA-3' and 5'-GGTGGGATACCTTGCGAATTAG-3'; RelA, 5'-CTGCCGGGATGGCTTCTAT-3' and 5'-CCAGGTTCTGGAAACTGTGGAT-3'. PCR contained 100 pmol of each primer and 1x SYBR Green Master Mix (PE Applied Biosystems) in a 25-µl volume. PCR cycling conditions were 95°C for 15 s and 60°C for 1 min for 40 cycles and conducted on an ABI PRISM 7700 thermal cycler (PE Applied Biosystems). Relative standard curves were generated for GAPDH, RelB, p50, p52, c-Rel, and RelA by plotting dilutions of B cell lymphoblastoid cell line cDNA of known RNA concentration against cycle threshold values. Using cycle threshold values obtained from MDDC cDNA and standard curves generated above, the amount of input RNA for GAPDH, RelB, p50, p52, c-Rel, and RelA was determined. By normalizing for different GAPDH input RNA levels, the relative amounts of NF-{kappa}B mRNA were determined and expressed as fold increase. Data are expressed as the mean ± SEM of two independent experiments using different donor MDDC.

Statistical analysis

Differences were analyzed using paired t tests.


    Results
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
TNF-{alpha} and CD40L differentially signal NF-{kappa}B-dependent APC function

CD40L and TNF-{alpha} induce DC maturation but induce different functional outcomes. Whereas TNF-{alpha} induces reversible maturation of MDDC, low levels of IL-12 secretion, and weak CTL induction, CD40L is a potent signal for IL-12 production and CTL activation. We hypothesized that CD40L and TNF-{alpha} would also differ in their capacity to activate DC NF-{kappa}B. DC differentiated for 2 days from monocytes in the presence of GM-CSF and IL-4 (MDDC) were used as a model. Two-day MDDC expressed low levels of CD14, CD83, and CD86, moderate CD40, and high levels of CD11c and HLA-DR (Fig. 1GoA). Constitutive RelB DNA binding activity was low (Fig. 1GoB), and their capacity to stimulate allogeneic T cell proliferation was modest (Fig. 1GoC). MDDC were stimulated for 24 h with increasing doses of TNF-{alpha} or CD40L and compared for nuclear RelB DNA binding activity by ELISA. Although both CD40L and TNF-{alpha} up-regulated DNA binding of RelB, CD40L induced higher levels of RelB DNA binding within the nucleus (Fig. 1GoB). Maximal RelB DNA binding activity was induced with 100 U/ml TNF-{alpha} and 500 ng/ml CD40L. Increased levels of NF-{kappa}B in CD40L-stimulated MDDC correlated with an enhanced ability of these cells to stimulate allogeneic T cells compared with DC treated with TNF-{alpha} (Fig. 1GoC) and higher levels of CD83, CD86, and HLA-DR surface expression (Fig. 2GoB). In summary, these data show a close correlation between RelB DNA binding activity and MDDC APC function.



View larger version (16K):
[in this window]
[in a new window]
 
FIGURE 1. Enhanced NF-{kappa}B activation is associated with APC function in MDDC treated with CD40L. A, Monocytes cultured for 48 h with GM-CSF and IL-4 were harvested and analyzed by FACS. Data are representative of at least four experiments. B, RelB DNA binding activity in nuclear extracts from MDDC treated for 24 h with increasing doses of TNF-{alpha} or CD40L was analyzed by ELISA. Data represent the mean of duplicate wells ± SEM and are representative of two separate experiments. C, Varying numbers of MDDC from the same donor were treated for 24 h with increasing doses of TNF-{alpha}, or CD40L were incubated with 105 purified allogeneic T cells for 5 days, and T cell proliferation was measured by incorporation of [3H]thymidine. Data represent the mean of triplicate wells ± SEM and are representative of two separate experiments.

 


View larger version (22K):
[in this window]
[in a new window]
 
FIGURE 2. Inhibition of NF-{kappa}B blocks functional MDDC maturation. A, p50, RelB, and RelA DNA binding activity in nuclear extracts from MDDC treated for 24 h with TNF-{alpha} or CD40L in the presence or absence of 1, 5, or 10 µM BAY 11-7082. B, MDDC treated for 24 h with TNF-{alpha} (left) or CD40L (right) in the presence or absence of 1, 5, or 10 µM BAY 11-7082 were stained with Abs to CD83, HLA-DR, and CD86 and analyzed by flow cytometry. Data are presented as change in mean fluorescence intensity from isotype control and are the mean of two separate experiments ± SEM. *, p < 0.05 vs MDDC stimulated with TNF-{alpha} or CD40L in absence of BAY. Open symbols indicate unstimulated MDDC controls. C, Varying numbers of MDDC treated for 24 h with TNF-{alpha} or CD40L in the presence or absence of 10 µM BAY 11-7082 were incubated with 105 purified allogeneic T cells for 5 days, and T cell proliferation was measured by incorporation of [3H]thymidine. Data are the mean of triplicate wells ± SEM and are representative of two separate experiments.

 
To assess the contribution of the NF-{kappa}B signaling pathway to TNF-{alpha}- and CD40L-induced MDDC maturation, the NF-{kappa}B pathway was inhibited at the time of maturation induction. The compound BAY 11-7082 has previously been shown to block NF-{kappa}B induction in endothelial cells through the inhibition of I{kappa}B{alpha} phosphorylation (20). MDDC were treated for 24 h with 100 U/ml TNF-{alpha} or 500 ng/ml CD40L, as these doses had been shown in the previous experiments to maximally induce RelB DNA binding and APC function. Treatment in the presence of BAY 11-7082 blocked DNA binding of RelB, p50, and RelA in a dose-dependent manner, with 10 µM effectively inhibiting NF-{kappa}B DNA binding (Fig. 2GoA). Consistent with the previously reported inhibitory effects of BAY 11-7082 on I{kappa}B processing, BAY 11-7082 inhibited TNF-{alpha}-induced nuclear translocation but not cytoplasmic expression of RelB and p50 (data not shown). BAY 11-7082 blocked CD40L and TNF-{alpha}-induced up-regulation of CD86, HLA-DR, and CD83 in a dose-dependent manner (Fig. 2GoB), although TNF-{alpha} induced lower levels of CD83 and HLA-DR than did CD40L. In addition, 10 µM BAY 11-7082 inhibited the up-regulation of DC APC function induced by CD40L or TNF-{alpha} (Fig. 2GoC). The data indicate that CD40L stimulation of MDDC induces higher levels of NF-{kappa}B DNA binding compared with TNF-{alpha}, and this correlates with enhanced APC function. Moreover, blockade of the NF-{kappa}B pathway is sufficient to completely prevent TNF-{alpha}- or CD40L-induced MDDC maturation associated with enhanced capacity for T cell activation.

CD40L signals sustained activation of NF-{kappa}B in MDDC

Because NF-{kappa}B activation is required for functional maturation of MDDC, signals that enhance the APC function of DC most effectively would be expected to have potent effects on NF-{kappa}B. To compare activation by CD40L and TNF-{alpha} in more detail, the kinetics of NF-{kappa}B induction were examined. Nuclear p50 and RelB were assessed by immunoblotting. Incubation of MDDC with 100 U/ml TNF-{alpha} or 500 ng/ml CD40L induced nuclear translocation of RelB and p50 in MDDC within 30 min (Fig. 3Go). Whereas TNF-{alpha} induced maximal nuclear translocation of RelB and p50 at 4 h, nuclear translocation continued for at least 24 h after stimulation with CD40L. In keeping with the dose-response curves shown in Fig. 1Go, neither 500 nor 1000 U/ml TNF-{alpha} increased the nuclear translocation of RelB after 4 h (data not shown).



View larger version (23K):
[in this window]
[in a new window]
 
FIGURE 3. Sustained induction of nuclear RelB and p50 translocation in MDDC treated with CD40L. A, Nuclear extracts prepared from MDDC stimulated with TNF-{alpha} or CD40L for various times were immunoblotted with anti-RelB and anti-p50. B, Quantitation of nuclear RelB and p50 by densitometry. Data are representative of two separate experiments.

 
The mechanism for sustained NF-{kappa}B induction by CD40L

Sustained transcriptional activation of RelB, p50, and c-Rel. The next series of experiments explored the mechanism behind the sustained induction of NF-{kappa}B by CD40L as opposed to TNF-{alpha}. We demonstrated previously that RelB activity in DC was regulated both transcriptionally and through nuclear translocation upon DC activation (17). To test whether TNF-{alpha} or CD40L also induced NF-{kappa}B mRNA in MDDC, levels of NF-{kappa}B mRNA were quantitatively analyzed by real-time PCR following activation. TNF-{alpha} signaled a 2-fold increase in RelB, c-Rel, and p50 mRNA within 30 min, increasing 4- to 5-fold by 2 h (Fig. 4Go). Whereas RelB mRNA levels remained elevated for 24 h, c-Rel and p50 mRNA levels returned almost to baseline levels by 24 h. The induction of RelB, c-Rel, and p50 mRNA by CD40L was slower than that induced by TNF-{alpha}, in that a 2-fold increase occurred within 1–2 h, and mRNA levels continued to increase for 6–24 h (Fig. 4Go). Neither RelA nor p52 mRNA was induced by either stimulus (Fig. 4Go and data not shown). The data indicate that signaling by either TNF-{alpha} or CD40L induces rapid nuclear translocation of RelB and p50 in 48-h MDDC. This translocation is accompanied by increased RelB, p50, and c-Rel mRNA. Sustained RelB/p50 translocation following CD40L treatment of DC is associated with a sustained increase in RelB, p50, and c-Rel mRNA.



View larger version (26K):
[in this window]
[in a new window]
 
FIGURE 4. Transcriptional activation of RelB by CD40L is prolonged. NF-{kappa}B mRNA levels from MDDC treated with TNF-{alpha} (open bars) and CD40L (filled bars) by real-time PCR. Results are normalized to GAPDH and expressed as fold increase relative to untreated control MDDC. Data are expressed as the mean ± SEM of two independent experiments using different donor MDDC.

 
Differential signaling of I{kappa}B{alpha}. Because retention of NF-{kappa}B in the cytoplasm by inhibitory proteins (I{kappa}B) is essential to NF-{kappa}B regulation, the attenuated nuclear translocation of NF-{kappa}B induced by TNF-{alpha} may be a consequence of increasing cytoplasmic retention by I{kappa}B. To test this, protein levels of the predominant I{kappa}B{alpha}, which has been shown to inhibit all NF-{kappa}B subunits, were examined in cytoplasmic extracts of MDDC stimulated with TNF-{alpha} or CD40L. Whereas TNF-{alpha} induced increasing cytoplasmic I{kappa}B{alpha} from 1 h onwards, CD40L induced maximal I{kappa}B{alpha} at 2 h that declined up until 24 h (Fig. 5Go). The decline in I{kappa}B{alpha} following CD40L stimulation coincided with the appearance of phosphorylated I{kappa}B{alpha} (Fig. 5GoA) and strong nuclear RelB/p50 location (Fig. 3Go). Because phosphorylated I{kappa}B{alpha} is actively degraded, the data indicate that, although I{kappa}B{alpha} is induced by CD40L treatment, active proteolysis prevents I{kappa}B{alpha} accumulation.



View larger version (31K):
[in this window]
[in a new window]
 
FIGURE 5. Reduced degradation of I{kappa}B{alpha} in MDDC in response to TNF-{alpha}. A, Cytoplasmic extracts prepared from MDDC stimulated with either TNF-{alpha} or CD40L were immunoblotted with anti-I{kappa}B{alpha} or anti-phospho-I{kappa}B{alpha} (Ser32). B, Quantitation of cytoplasmic I{kappa}B{alpha} by densitometry. Data are representative of two separate experiments.

 
IL-10 induced by TNF-{alpha} is inhibitory for NF-{kappa}B. TNF-{alpha} stimulation of monocytes induces IL-10, and LPS and other signals stimulate autocrine IL-10 production by immature MDDC that can inhibit maturation, IL-10, and I{kappa}B (21, 22). Using the previous model, the next experiments tested whether IL-10 regulated nuclear RelB translocation by TNF-{alpha}. Initially, levels of IL-10 in supernatants of MDDC stimulated for 24 h in the presence of TNF-{alpha}, LPS, or CD40L were determined. Whereas stimulation of MDDC with CD40L failed to induce IL-10, both TNF-{alpha} and LPS stimulation induced IL-10 by ~5- and 10-fold, respectively (Table IGo). Inhibition of IL-10 by addition of anti-IL-10 neutralizing Ab enhanced TNF-{alpha}-induced RelB translocation at 24 h (Fig. 6Go, A and B). In addition, anti-IL-10 increased RelB DNA binding activity and APC function of TNF-{alpha}-stimulated MDDC to levels similar to those observed for CD40L-stimulated MDDC (Fig. 6Go, A and B). These effects were mediated via NF-{kappa}B, as addition of 10 µM Bay 11-7082 reversed the effects of IL-10 neutralization on RelB DNA binding and APC function (Figs. 6Go, C and D). These data indicate that autocrine IL-10 is sufficient to attenuate NF-{kappa}B activation of MDDC in response to TNF-{alpha}.


View this table:
[in this window]
[in a new window]
 
Table I. Cytokine production by MDDC1

 


View larger version (20K):
[in this window]
[in a new window]
 
FIGURE 6. Blocking IL-10 leads to sustained NF-{kappa}B translocation in response to TNF-{alpha}. A, Nuclear extracts from MDDC treated for 6 or 24 h with TNF-{alpha} in the presence or absence of anti-IL-10, anti-IL-12, or control Ig were immunoblotted with anti-RelB. B, Quantitation of nuclear RelB by densitometry. Data are representative of two separate experiments. C, RelB DNA binding activity in MDDC treated for 24 h with TNF-{alpha} in the presence or absence of anti-IL-10 and 10 µM BAY 11-7082. D, Varying numbers of MDDC treated for 24 h with TNF-{alpha} in the presence or absence of anti-IL-10 and 10 µM BAY 11-7082 were incubated with 105 purified allogeneic T cells for 5 days, and T cell proliferation was measured by incorporation of [3H]thymidine. Data are the mean of triplicate wells ± SEM and are representative of two separate experiments.

 
Sustained induction of NF-{kappa}B by CD40L rather than downstream IL-12 production. Twenty-four-hour stimulation of MDDC with TNF-{alpha}, CD40L, or LPS induced 3-, 9-, and 40-fold higher levels of IL-12 p70 produced in supernatant compared with unstimulated MDDC (Table IGo). To determine whether IL-12 produced in response to CD40L might influence RelB nuclear translocation, anti-IL-12 neutralizing Ab was added to MDDC in the presence of TNF-{alpha} or CD40L. Inhibition of IL-12 had no effect on TNF-{alpha}-induced RelB translocation (Fig. 6Go, A and B), modestly reduced CD40L-induced RelB translocation at 24 h (Fig. 6Go, A and B), and had no effect on the APC function of DC in response to CD40L (Fig. 7GoA). While addition of exogenous IL-12 to MDDC strongly induced RelB, p50, and c-Rel mRNA after 24 h, RelB, p50, and RelA nuclear DNA binding was only weakly induced (Figs. 7Go, B and C). Therefore, although exogenous IL-12 can induce NF-{kappa}B activation, this induction is weak, and IL-12 produced in response to CD40L contributes to MDDC NF-{kappa}B translocation only minimally, at least at 24 h.



View larger version (18K):
[in this window]
[in a new window]
 
FIGURE 7. Modest effects of autocrine IL-12 on NF-{kappa}B in MDDC following CD40L. A, Varying numbers of MDDC treated for 24 h with CD40L in the presence or absence of anti-IL-10, anti-IL-12, or control Ig were incubated with 105 purified allogeneic T cells for 5 days, and T cell proliferation was measured by incorporation of [3H]thymidine. Data are the mean of triplicate wells ± SEM and are representative of two separate experiments. B, NF-{kappa}B mRNA levels from MDDC treated with IL-12 for 24 h. Results are normalized to GAPDH and expressed as fold increase relative to untreated control MDDC. C, p50, RelB, and RelA DNA binding activity in nuclear extracts from MDDC treated for 24 h with IL-12. Data represent the mean of duplicate wells ± SEM and are representative of two separate experiments.

 

    Discussion
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
DCs have a specialized role in regulating T cell responses. Although the role of DC in priming Ag-specific immune responses is well established, DC may also constitutively present self Ag in the draining lymph node in a nonimmunogenic fashion to maintain peripheral tolerance (23, 24). T cell responses are regulated by the Ag dose, type of DC, and state of DC activation (25). Because DC, particularly MDDC, are currently used in many clinical trials for enhancing immune responses to tumors (26), an understanding of the signaling pathways leading to IL-12 and other cytokine production and effective T cell activation is critical. The current studies demonstrate that blockade of the NF-{kappa}B pathway is sufficient to prevent MDDC maturation, induced by maximal doses of TNF-{alpha} or CD40L, and associated enhanced capacity for T cell activation. Collectively, these data indicate that NF-{kappa}B activation is required for functional maturation of MDDC and strongly implicate NF-{kappa}B in the coordinate up-regulation of cell surface molecules associated with enhanced APC function. These data reinforce previous observations that the NF-{kappa}B pathway is activated during DC maturation by diverse signals such as microbial products, inflammatory cytokines, and CD40L (15, 16, 27, 28, 29, 30, 31, 32), and that maturation of MDDC can be blocked by overexpression of I{kappa}B{alpha} or by use of a cell-permeable peptide to prevent NF-{kappa}B nuclear localization (27, 33). However, not all signals induce equivalent DC activation, and as a result different proinflammatory signals translate to different T cell outcomes. For example, TNF-{alpha} induces reversible DC maturation, low levels of IL-12, and weak CTL, while CD40L stimulates high levels of IL-12 and is a key conditioning stimulus for CTL activation (6, 7, 8).

Given that TNF-{alpha} and CD40L induce maturation of DC through NF-{kappa}B activation but lead to different functional outcomes, the current studies examined whether these signals differ in their capacity to activate NF-{kappa}B. Indeed, CD40L induced sustained high levels of RelB/p50 activation in MDDC. This occurred by several mechanisms. In peripheral blood DC precursors, RelB activity is regulated both at the mRNA level and through nuclear translocation (17). Stimulation of MDDC by TNF-{alpha} and CD40L revealed striking differences in RelB, p50, and c-Rel mRNA levels. RelB, p50, and c-Rel mRNA was rapidly induced and rapidly attenuated in response to TNF-{alpha}. In contrast, RelB, p50, and c-Rel mRNA was induced by CD40L more slowly, but higher levels of RelB and c-Rel were induced, and RelB mRNA was increasing even 24 h later. The selective induction of RelB, p50, and c-Rel mRNA implicates these subunits in NF-{kappa}B transcriptional autoregulation. Of interest, despite differences in the intensity with each signal, NF-{kappa}B activation in D1 cells stimulated with either live bacteria or LPS showed similar attenuation at 24 h as observed here for TNF-{alpha} stimulation (29).

TNF-{alpha} and CD40L also differed in their capacity to degrade I{kappa}B. I{kappa}B proteins regulate NF-{kappa}B through cytoplasmic retention. Although five mammalian I{kappa}B proteins have been characterized, I{kappa}B{alpha} is likely to play a major role in repression of NF-{kappa}B in MDDC. First, I{kappa}B{alpha} is expressed at high levels by MDDC (16) and can inhibit transactivation of all known NF-{kappa}B subunit combinations (34). Second, ectopic expression of I{kappa}B{alpha} in MDDC can inhibit NF-{kappa}B nuclear translocation (33). However, other proteins, including p105 and p100, may also be important (35). In the current studies cytoplasmic I{kappa}B{alpha} levels increased several hours after CD40L or TNF-{alpha} stimulation of MDDC. Moreover, in the presence of CD40L for 24 h, hyperphosphorylated I{kappa}B{alpha} appeared, suggesting that I{kappa}B{alpha} is actively degraded. Together with the mRNA data, this suggests a further mechanism for the sustained nuclear induction of RelB/p50 after CD40 ligation, in that newly synthesized p50 and RelB could associate and translocate to the nucleus.

Consistent with the increasing cytoplasmic expression of I{kappa}B{alpha} and with the ability of IL-10 to inhibit IKK activity and NF-{kappa}B DNA binding (36), the current studies also indicate that autocrine IL-10, produced in response to TNF-{alpha} but not CD40L, moderates NF-{kappa}B activity of MDDC. IL-10 has potent anti-inflammatory effects ranging from induction of anti-inflammatory soluble TNFR and IL-1R antagonist to down-regulation of APC function (37, 38). Previously, neutralization of IL-10 has been shown to enhance the capacity of 6-day MDDC to stimulate T cell proliferation and IFN-{gamma} production following LPS or CD40L signaling (22). In the current studies, anti-IL-10 produced only modest enhancement of NF-{kappa}B translocation in response to CD40L and did not affect APC function. These differences almost certainly relate to differences in IL-10 production by MDDC harvested at days 2 or 6. Moderation of DC APC function by exogenous IL-10 in the presence of TNF-{alpha} or CD40L has been shown previously; however, due to reduced IL-10R expression upon DC maturation, the effect of exogenous IL-10 varies depending on the activation state of the DC at the time of IL-10 exposure (32, 39). In contrast to TNF-{alpha}, CD40L provides a strong, sustained NF-{kappa}B activation signal to MDDC that is only somewhat dependent, at 24 h, on autocrine IL-12 signaling of NF-{kappa}B. This is in keeping with the relatively weak activation of NF-{kappa}B by exogenous IL-12. Although it is possible that IL-12 might have more prolonged effects on DC differentiation than were examined in this work, it is more likely that the major mechanisms for sustained NF-{kappa}B translocation in response to CD40L relate to positive transcriptional feedback and enhanced I{kappa}B phosphorylation. Taken together with functional inhibition of MDDC by NF-{kappa}B inhibitors, the data strongly support the idea that NF-{kappa}B plays a central role in transducing environmental signals such as TNF-{alpha}, LPS, IL-12, CD40L, and IL-10 for modulation of DC function. Clearly, the data imply that the microenvironment of the DC will have a major impact on its APC function.

Although both TNF-{alpha} and CD40L activate NF-{kappa}B through specific receptors via common TNFR-associated factor and NF-{kappa}B-inducing kinases, the two stimuli differ in their ability to induce IL-10. The mechanism behind selective IL-10 induction is unknown; however, it may be through posttranscriptional regulation of IL-10, as transcription is regulated by ubiquitous transcription factors Sp1 and Sp3 (40, 41). Irrespective of the mechanism of IL-10 induction, IL-10 has the capacity to act in an autocrine manner to signal through the IL-10R and to suppress nuclear activity of NF-{kappa}B. Signaling via IL-10R activates Janus kinase 1 and tyrosine kinase 2, as well as the latent transcription factors STAT1 and STAT3, leading to inhibition of proinflammatory cytokines, chemokines, and Ag-presenting function (42). The likely mechanism of this inhibition is through IL-10-induced transcription of suppressors of cytokine signaling-3 genes, which have proinflammatory attenuating functions (43).

The current studies have important implications for design of tumor immunotherapy. Conditioning DC with signals such as CD40 ligation or viral infection is necessary for activation of CTL in lymph nodes (7). The potent and sustained effect of CD40 ligation on NF-{kappa}B nuclear translocation shown in this work provides at least one explanation for the exquisite sensitivity of CD40L for CTL activation in draining lymph nodes, as NF-{kappa}B, particularly RelB, transcriptionally activates MHC class I and CD40 itself (18, 44). Similarly, DC treated with CD40L and pulsed with tumor Ag enhance antitumor CTL and CD4+ T cell responses (9). In contrast, immunosuppressive cytokines such as IL-10, TGF-{beta}, and vascular endothelial growth factor (32, 45, 46) regulate DC maturation and function in tumor environments as well as in normal skin, lung, or gut epithelium. These cytokines reduce NF-{kappa}B activity and contribute to the prevention of DC differentiation in these environments. Therefore, NF-{kappa}B is a central biochemical pathway that regulates DC function in response to environmental signals. This implies that signals transduced by NF-{kappa}B in DC ex vivo or in vivo will influence T cell responses in immunotherapy, and that sustained activation of NF-{kappa}B, particularly RelB, can be used as an effective read-out of the functional status of a DC when designing immunotherapeutic strategies.


    Acknowledgments
 
We thank Prof. Ian Frazer and Dr. Nick Saunders for critical reading of the manuscript.


    Footnotes
 
1 This work was supported by the National Health and Medical Research Council of Australia. R.T. is supported by the Arthritis Foundation of Queensland. Back

2 Address correspondence and reprint requests to Dr. Ranjeny Thomas, Center for Immunology and Cancer Research, University of Queensland, Princess Alexandra Hospital, Ipswich Road, Woolloongabba, Brisbane, Queensland 4102, Australia. E-mail address: rthomas{at}medicine.pa.uq.edu.au Back

3 Abbreviations used in this paper: DC, dendritic cell; CD40L, CD40 ligand; MDDC, monocyte-derived DC. Back

Received for publication December 26, 2001. Accepted for publication March 21, 2002.


    References
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Yewdell, J. W., C. C. Norbury, J. R. Bennink. 1999. Mechanisms of exogenous antigen presentation by MHC class I molecules in vitro and in vivo: implications for generating CD8+ T cell responses to infectious agents, tumors, transplants, and vaccines. Adv. Immunol. 73:1.[Medline]
  2. Hartmann, G., G. J. Weiner, A. M. Krieg. 1999. CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc. Natl. Acad. Sci. USA 96:9305.[Abstract/Free Full Text]
  3. Rescigno, M., F. Granucci, S. Citterio, M. Foti, P. Ricciardi-Castagnoli. 1999. Coordinated events during bacteria-induced DC maturation. Immunol. Today 20:200.[Medline]
  4. Cella, M., D. Scheidegger, K. Palmer-Lehmann, P. Lane, A. Lanzavecchia, G. Alber. 1996. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. 184:747.[Abstract/Free Full Text]
  5. Banchereau, J., F. Briere, C. Caux, J. Davoust, S. Lebecque, Y. J. Liu, B. Pulendran, K. Palucka. 2000. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18:767.[Medline]
  6. Bennett, S. R., F. R. Carbone, F. Karamalis, R. A. Flavell, J. F. Miller, W. R. Heath. 1998. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393:478.[Medline]
  7. Ridge, J. P., F. Di Rosa, P. Matzinger. 1998. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and T-killer cell. Nature 393:474.[Medline]
  8. Schoenberger, S. P., R. E. M. Toes, E. I. H. van der Voort, R. Offringa, C. J. M. Melief. 1998. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393:480.[Medline]
  9. Labeur, M. S., B. Roters, B. Pers, A. Mehling, T. A. Luger, T. Schwartz, S. Grabbe. 1999. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J. Immunol. 162:168.[Abstract/Free Full Text]
  10. Ghosh, S., M. J. May, E. B. Kopp. 1998. NF-{kappa}B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 16:225.[Medline]
  11. Garceau, N., Y. Kosaka, S. Masters, J. Hambor, R. Shinkura, T. Honjo, R. J. Noelle. 2000. Lineage-restricted function of nuclear factor {kappa}B-inducing kinase (NIK) in transducing signals via CD40. J. Exp. Med. 191:381.[Abstract/Free Full Text]
  12. Burkly, L., C. Hession, L. Ogata, C. Reilly, L. A. Marconi, D. Olson, R. Tizard, R. Cate, D. Lo. 1995. Expression of relB is required for the development of thymic medulla and dendritic cells. Nature 373:531.[Medline]
  13. DiMolfetto, L., C. Reilly, Q. Wei, D. Lo. 1997. Dendritic-like cells from relB mutant mice. Adv. Exp. Med. Biol. 417:47.[Medline]
  14. Weih, F., G. Warr, H. Yang, R. Bravo. 1997. Multifocal defects in immune responses in RelB-deficient mice. J. Immunol. 158:5211.[Abstract]
  15. Ammon, C., K. Mondal, R. Andreesen, S. W. Krause. 2000. Differential expression of the transcription factor NF-{kappa}B during human mononuclear phagocyte differentiation to macrophages and dendritic cells. Biochim. Biophys. Acta 268:99.
  16. Neumann, M., H. Fries, C. Scheicher, P. Keikavoussi, A. Kolb-Maurer, E. Brocker, E. Serfling, E. Kampgen. 2000. Differential expression of Rel/NF-{kappa}B and octamer factors is a hallmark of the generation and maturation of dendritic cells. Blood 95:277.[Abstract/Free Full Text]
  17. Pettit, A. R., C. Quinn, K. P. MacDonald, L. L. Cavanagh, G. Thomas, W. Townsend, M. Handel, R. Thomas. 1997. Nuclear localization of RelB is associated with effective APC function. J. Immunol. 159:3681.[Abstract]
  18. O’Sullivan, B. J., K. P. MacDonald, A. R. Pettit, R. Thomas. 2000. RelB nuclear translocation regulates B cell MHC molecule, CD40 expression, and antigen-presenting cell function. Proc. Natl. Acad. Sci. USA 97:11421.[Abstract/Free Full Text]
  19. Cavanagh, L. L., R. J. Saal, K. L. Grimmett, R. Thomas. 1998. Proliferation in monocyte-derived dendritic cell cultures is caused by progenitor cells capable of myeloid differentiation. Blood 92:1598.[Abstract/Free Full Text]
  20. Pierce, J. W., R. Schoenleber, G. Jesmok, J. Best, S. A. Moore, T. Collins, M. E. Gerritsen. 1997. Novel inhibitors of cytokine-induced I{kappa}B{alpha} phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J. Biol. Chem. 272:21096.[Abstract/Free Full Text]
  21. Platzer, C., C. Meisel, K. Vogt, M. Platzer, H. D. Volk. 1995. Up-regulation of monocytic IL-10 by tumor necrosis factor-{alpha} and cAMP elevating drugs. Int. Immunol. 7:517.[Abstract/Free Full Text]
  22. Corinti, S., C. Albanesi, A. la Sala, S. Pastore, G. Girolomoni. 2001. Regulatory activity of autocrine IL-10 on dendritic cell functions. J. Immunol. 166:4312.[Abstract/Free Full Text]
  23. Steinman, R. M., S. Turley, I. Mellman, K. Inaba. 2000. The induction of tolerance by dendritic cells that have captured apoptotic cells. J. Exp. Med. 191:411.[Free Full Text]
  24. Jonuleit, H., E. Schmitt, K. Steinbrink, A. H. Enk. 2001. Dendritic cells as a tool to induce anergic and regulatory T cells. Trends Immunol. 22:394.[Medline]
  25. Lanzavecchia, A., F. Sallusto. 2000. Dynamics of T lymphocyte responses: intermediates, effectors, and memory cells. Science 290:92.[Abstract/Free Full Text]
  26. Bocchia, M., V. Bronte, M. P. Colombo, A. De Vincentiis, M. Di Nicola, G. Forni, L. Lanata, R. M. Lemoli, M. Massaia, D. Rondelli, et al 2000. Antitumor vaccination: where we stand. Haematologica 85:1172.[Abstract/Free Full Text]
  27. Ardeshna, K. M., A. R. Pizzey, S. Devereux, A. Khwaja. 2000. The PI3 kinase, p38 SAP kinase, and NF-{kappa}B signal transduction pathways are involved in the survival and maturation of lipopolysaccharide-stimulated human monocyte-derived dendritic cells. Blood 96:1039.[Abstract/Free Full Text]
  28. Arrighi, J. F., M. Rebsamen, F. Rousset, V. Kindler, C. Hauser. 2001. A critical role for p38 mitogen-activated protein kinase in the maturation of human blood-derived dendritic cells induced by lipopolysaccharide, TNF-{alpha}, and contact sensitizers. J. Immunol. 166:3837.[Abstract/Free Full Text]
  29. Hofer, S., M. Rescigno, F. Granucci, S. Citterio, M. Francolini, P. Ricciardi-Castagnoli. 2001. Differential activation of NF-{kappa}B subunits in dendritic cells in response to Gram-negative bacteria and to lipopolysaccharide. Microbes Infect. 3:259.[Medline]
  30. Lyakh, L. A., G. K. Koski, W. Telford, R. E. Gress, P. A. Cohen, N. R. Rice. 2000. Bacterial lipopolysaccharide, TNF-{alpha}, and calcium ionophore under serum-free conditions promote rapid dendritic cell-like differentiation in CD14+ monocytes through distinct pathways that activate NF-{kappa}B. J. Immunol. 165:3647.[Abstract/Free Full Text]
  31. Aicher, A., G. L. Shu, D. Magaletti, T. Mulvania, A. Pezzutto, A. Craxton, E. A. Clark. 1999. Differential role for p38 mitogen-activated protein kinase in regulating CD40-induced gene expression in dendritic cells and B cells. J. Immunol. 163:5786.[Abstract/Free Full Text]
  32. Brossart, P., A. Zobywalski, F. Grunebach, L. Behnke, G. Stuhler, V. L. Reichardt, L. Kanz, W. Brugger. 2000. Tumor necrosis factor {alpha} and CD40 ligand antagonize the inhibitory effects of interleukin 10 on T-cell stimulatory capacity of dendritic cells. Cancer Res. 60:4485.[Abstract/Free Full Text]
  33. Yoshimura, S., J. Bondeson, B. M. Foxwell, F. M. Brennan, M. Feldmann. 2001. Effective antigen presentation by dendritic cells is NF-{kappa}B dependent: coordinate regulation of MHC, co-stimulatory molecules and cytokines. Int. Immunol. 13:675.[Abstract/Free Full Text]
  34. Dobrzanski, P., R. P. Ryseck, R. Bravo. 1994. Differential interactions of Rel-NF-{kappa}B complexes with I{kappa}B{alpha} determine pools of constitutive and inducible NF-{kappa}B activity. EMBO J. 13:4608.[Medline]
  35. Solan, N. J., H. Miyoshi, E. M. Carmona, G. D. Bren, C. V. Paya. 2002. RelB cellular regulation and transcriptional activity are regulated by p100. J. Biol. Chem. 277:1405.[Abstract/Free Full Text]
  36. Schottelius, A. J., M. W. Mayo, R. B. Sartor, Jr A. S. Baldwin. 1999. Interleukin-10 signaling blocks inhibitor of {kappa}B kinase activity and nuclear factor {kappa}B DNA binding. J. Biol. Chem. 274:31868.[Abstract/Free Full Text]
  37. Buelens, C., V. Verhasselt, D. De Groote, K. Thielemans, M. Goldman, F. Willems. 1997. Interleukin-10 prevents the generation of dendritic cells from human peripheral blood mononuclear cells cultured with interleukin-4 and granulocyte/macrophage-colony-stimulating factor. Eur. J. Immunol. 27:756.[Medline]
  38. Allavena, P., L. Piemonti, D. Longoni, S. Bernasconi, A. Stoppacciaro, L. Ruco, A. Mantovani. 1998. IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. Eur. J. Immunol. 28:359.[Medline]
  39. MacDonald, K. P., A. R. Pettit, C. Quinn, G. J. Thomas, R. Thomas. 1999. Resistance of rheumatoid synovial dendritic cells to the immunosuppressive effects of IL-10. J. Immunol. 163:5599.[Abstract/Free Full Text]
  40. Tone, M., M. J. Powell, Y. Tone, S. A. Thompson, H. Waldmann. 2000. IL-10 gene expression is controlled by the transcription factors Sp1 and Sp3. J. Immunol. 165:286.[Abstract/Free Full Text]
  41. Powell, M. J., S. A. Thompson, Y. Tone, H. Waldmann, M. Tone. 2000. Posttranscriptional regulation of IL-10 gene expression through sequences in the 3'-untranslated region. J. Immunol. 165:292.[Abstract/Free Full Text]
  42. Moore, K. W., R. de Waal Malefyt, R. L. Coffman, A. O’Garra. 2001. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19:683.[Medline]
  43. Cassatella, M. A., S. Gasperini, C. Bovolenta, F. Calzetti, M. Vollebregt, P. Scapini, M. Marchi, R. Suzuki, A. Suzuki, A. Yoshimura. 1999. Interleukin-10 (IL-10) selectively enhances CIS3/SOCS3 mRNA expression in human neutrophils: evidence for an IL-10-induced pathway that is independent of STAT protein activation. Blood 94:2880.[Abstract/Free Full Text]
  44. Dejardin, E., V. Deregowski, R. Greimers, Z. Cai, S. Chouaib, M. P. Merville, V. Bours. 1998. Regulation of major histocompatibility complex class I expression by NF-{kappa}B-related proteins in breast cancer cells. Oncogene 16:3299.[Medline]
  45. Strobl, H., W. Knapp. 1999. TGF-{beta}1 regulation of dendritic cells. Microbes Infect. 1:1283.[Medline]
  46. Oyama, T., S. Ran, T. Ishida, S. Nadaf, L. Kerr, D. P. Carbone, D. I. Gabrilovich. 1998. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of NF-{kappa}B activation in hemopoietic progenitor cells. J. Immunol. 160:1224.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
J. Immunol.Home page
C. Capini, M. Jaturanpinyo, H.-I Chang, S. Mutalik, A. McNally, S. Street, R. Steptoe, B. O'Sullivan, N. Davies, and R. Thomas
Antigen-Specific Suppression of Inflammatory Arthritis Using Liposomes
J. Immunol., March 15, 2009; 182(6): 3556 - 3565.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
H. M. Rowe, L. Lopes, N. Brown, S. Efklidou, T. Smallie, S. Karrar, P. M. Kaye, and M. K. Collins
Expression of vFLIP in a Lentiviral Vaccine Vector Activates NF-{kappa}B, Matures Dendritic Cells, and Increases CD8+ T-Cell Responses
J. Virol., February 15, 2009; 83(4): 1555 - 1562.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. J. Baglole, S. B. Maggirwar, T. A. Gasiewicz, T. H. Thatcher, R. P. Phipps, and P. J. Sime
The Aryl Hydrocarbon Receptor Attenuates Tobacco Smoke-induced Cyclooxygenase-2 and Prostaglandin Production in Lung Fibroblasts through Regulation of the NF-{kappa}B Family Member RelB
J. Biol. Chem., October 24, 2008; 283(43): 28944 - 28957.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
Z. U. A. Mollah, S. Pai, C. Moore, B. J. O'Sullivan, M. J. Harrison, J. Peng, K. Phillips, J. B. Prins, J. Cardinal, and R. Thomas
Abnormal NF-{kappa}B Function Characterizes Human Type 1 Diabetes Dendritic Cells and Monocytes
J. Immunol., March 1, 2008; 180(5): 3166 - 3175.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
N. Ade, D. Antonios, S. Kerdine-Romer, F. Boisleve, F. Rousset, and M. Pallardy
NF-{kappa}B Plays a Major Role in the Maturation of Human Dendritic Cells Induced by NiSO4 but not by DNCB
Toxicol. Sci., October 1, 2007; 99(2): 488 - 501.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
K. P. A. MacDonald, R. D. Kuns, V. Rowe, E. S. Morris, T. Banovic, H. Bofinger, B. O'Sullivan, K. A. Markey, A. L. Don, R. Thomas, et al.
Effector and regulatory T-cell function is differentially regulated by RelB within antigen-presenting cells during GVHD
Blood, June 1, 2007; 109(11): 5049 - 5057.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Li, X. Zhang, X. Zheng, D. Lian, Z.-X. Zhang, W. Ge, J. Yang, C. Vladau, M. Suzuki, D. Chen, et al.
Immune Modulation and Tolerance Induction by RelB-Silenced Dendritic Cells through RNA Interference
J. Immunol., May 1, 2007; 178(9): 5480 - 5487.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
L. Klotz, I. Dani, F. Edenhofer, L. Nolden, B. Evert, B. Paul, W. Kolanus, T. Klockgether, P. Knolle, and L. Diehl
Peroxisome Proliferator-Activated Receptor {gamma} Control of Dendritic Cell Function Contributes to Development of CD4+ T Cell Anergy
J. Immunol., February 15, 2007; 178(4): 2122 - 2131.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
F. Moore, S. Buonocore, E. Aksoy, N. Ouled-Haddou, S. Goriely, E. Lazarova, F. Paulart, C. Heirman, E. Vaeremans, K. Thielemans, et al.
An Alternative Pathway of NF-{kappa}B Activation Results in Maturation and T Cell Priming Activity of Dendritic Cells Overexpressing a Mutated I{kappa}B{alpha}
J. Immunol., February 1, 2007; 178(3): 1301 - 1311.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
E. Assier, V. Marin-Esteban, A. Haziot, E. Maggi, D. Charron, and N. Mooney
TLR7/8 agonists impair monocyte-derived dendritic cell differentiation and maturation
J. Leukoc. Biol., January 1, 2007; 81(1): 221 - 228.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
P. Sun, C. M. Celluzzi, M. Marovich, H. Subramanian, M. Eller, S. Widjaja, D. Palmer, K. Porter, W. Sun, and T. Burgess
CD40 Ligand Enhances Dengue Viral Infection of Dendritic Cells: A Possible Mechanism for T Cell-Mediated Immunopathology
J. Immunol., November 1, 2006; 177(9): 6497 - 6503.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
Y.-L. Lin, S.-S. Lee, S.-M. Hou, and B.-L. Chiang
Polysaccharide Purified from Ganoderma lucidum Induces Gene Expression Changes in Human Dendritic Cells and Promotes T Helper 1 Immune Response in BALB/c Mice
Mol. Pharmacol., August 1, 2006; 70(2): 637 - 644.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. I. Iruretagoyena, S. E. Sepulveda, J. P. Lezana, M. Hermoso, M. Bronfman, M. A. Gutierrez, S. H. Jacobelli, and A. M. Kalergis
Inhibition of Nuclear Factor-{kappa}B Enhances the Capacity of Immature Dendritic Cells to Induce Antigen-Specific Tolerance in Experimental Autoimmune Encephalomyelitis
J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 59 - 67.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
B. J. O'Sullivan, H. E. Thomas, S. Pai, P. Santamaria, Y. Iwakura, R. J. Steptoe, T. W. H. Kay, and R. Thomas
IL-1beta Breaks Tolerance through Expansion of CD25+ Effector T Cells.
J. Immunol., June 15, 2006; 176(12): 7278 - 7287.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
B. Blanco, J. A. Perez-Simon, L. I. Sanchez-Abarca, X. Carvajal-Vergara, J. Mateos, B. Vidriales, N. Lopez-Holgado, P. Maiso, M. Alberca, E. Villaron, et al.
Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines
Blood, May 1, 2006; 107(9): 3575 - 3583.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. D. Recklies, H. Ling, C. White, and S. M. Bernier
Inflammatory Cytokines Induce Production of CHI3L1 by Articular Chondrocytes
J. Biol. Chem., December 16, 2005; 280(50): 41213 - 41221.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. O'Keeffe, R. J. Grumont, H. Hochrein, M. Fuchsberger, R. Gugasyan, D. Vremec, K. Shortman, and S. Gerondakis
Distinct roles for the NF-{kappa}B1 and c-Rel transcription factors in the differentiation and survival of plasmacytoid and conventional dendritic cells activated by TLR-9 signals
Blood, November 15, 2005; 106(10): 3457 - 3464.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
K. Vermaelen and R. Pauwels
Pulmonary Dendritic Cells
Am. J. Respir. Crit. Care Med., September 1, 2005; 172(5): 530 - 551.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
Y.-L. Lin, Y.-C. Liang, S.-S. Lee, and B.-L. Chiang
Polysaccharide purified from Ganoderma lucidum induced activation and maturation of human monocyte-derived dendritic cells by the NF-{kappa}B and p38 mitogen-activated protein kinase pathways
J. Leukoc. Biol., August 1, 2005; 78(2): 533 - 543.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. Bayry, S. Lacroix-Desmazes, V. Donkova-Petrini, C. Carbonneil, N. Misra, Y. Lepelletier, S. Delignat, S. Varambally, E. Oksenhendler, Y. Levy, et al.
Natural antibodies sustain differentiation and maturation of human dendritic cells
PNAS, September 28, 2004; 101(39): 14210 - 14215.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Bhattacharyya, P. Sen, M. Wallet, B. Long, A. S. Baldwin Jr, and R. Tisch
Immunoregulation of dendritic cells by IL-10 is mediated through suppression of the PI3K/Akt pathway and of I{kappa}B kinase activity
Blood, August 15, 2004; 104(4): 1100 - 1109.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. G. Thompson, B. J. O'Sullivan, H. Beamish, and R. Thomas
T Cells Signaled by NF-{kappa}B- Dendritic Cells Are Sensitized Not Anergic to Subsequent Activation
J. Immunol., August 1, 2004; 173(3): 1671 - 1680.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
M. Movassagh, D. Laderach, and A. Galy
Proteins of the Ikaros family control dendritic cell maturation required to induce optimal Th1 T cell differentiation
Int. Immunol., June 1, 2004; 16(6): 867 - 875.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
N. J. Mason, H.-C. Liou, and C. A. Hunter
T Cell-Intrinsic Expression of c-Rel Regulates Th1 Cell Responses Essential for Resistance to Toxoplasma gondii
J. Immunol., March 15, 2004; 172(6): 3704 - 3711.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
J. G. Elliot, C. M. Jensen, S. Mutavdzic, J. P. Lamb, N. G. Carroll, and A. L. James
Aggregations of Lymphoid Cells in the Airways of Nonsmokers, Smokers, and Subjects with Asthma
Am. J. Respir. Crit. Care Med., March 15, 2004; 169(6): 712 - 718.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
D. Frleta, R. J. Noelle, and W. F. Wade
CD40-mediated up-regulation of Toll-like receptor 4-MD2 complex on the surface of murine dendritic cells
J. Leukoc. Biol., December 1, 2003; 74(6): 1064 - 1073.
[Abstract] [Full Text]


Home page
J. Immunol.Home page
J. Xie, J. Qian, S. Wang, M. E. Freeman III, J. Epstein, and Q. Yi
Novel and Detrimental Effects of Lipopolysaccharide on In Vitro Generation of Immature Dendritic Cells: Involvement of Mitogen-Activated Protein Kinase p38
J. Immunol., November 1, 2003; 171(9): 4792 - 4800.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
D. Laderach, D. Compagno, O. Danos, W. Vainchenker, and A. Galy
RNA Interference Shows Critical Requirement for NF-{kappa}B p50 in the Production of IL-12 by Human Dendritic Cells
J. Immunol., August 15, 2003; 171(4): 1750 - 1757.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Hewison, L. Freeman, S. V. Hughes, K. N. Evans, R. Bland, A. G. Eliopoulos, M. D. Kilby, P. A. H. Moss, and R. Chakraverty
Differential Regulation of Vitamin D Receptor and Its Ligand in Human Monocyte-Derived Dendritic Cells
J. Immunol., June 1, 2003; 170(11): 5382 - 5390.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. Xie, Y. Wang, M. E. Freeman III, B. Barlogie, and Q. Yi
beta 2-Microglobulin as a negative regulator of the immune system: high concentrations of the protein inhibit in vitro generation of functional dendritic cells
Blood, May 15, 2003; 101(10): 4005 - 4012.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
K. Duperrier, A. Farre, J. Bienvenu, N. Bleyzac, J. Bernaud, L. Gebuhrer, D. Rigal, and A. Eljaafari
Cyclosporin A inhibits dendritic cell maturation promoted by TNF-{alpha} or LPS but not by double-stranded RNA or CD40L
J. Leukoc. Biol., November 1, 2002; 72(5): 953 - 961.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by O’Sullivan, B. J.
Right arrow Articles by Thomas, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by O’Sullivan, B. J.
Right arrow Articles by Thomas, R.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS